Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...

Auron has dosed the first subject in the Phase I trial of AUTX-703, targeting individuals with advanced haematologic ...

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been ...

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Pfizer’s and Arvinas’ vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) ER degrader which slows tumour growth.